{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:53:00Z","timestamp":1775595180422,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"DOI":"10.7759\/cureus.91628","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T03:28:03Z","timestamp":1757042883000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Predictors of Progression From Metabolic Dysfunction-Associated Steatotic Liver Disease to Cirrhosis: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Jane M","family":"Abucha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekdes M","family":"Wollel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nethra","family":"Somannagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alousious","family":"Kasagga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayam","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gichin","family":"Changaramkumarath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.46439\/toxicology.6.030","article-title":"Non-alcoholic fatty liver disease: genetic susceptibility","volume":"6","author":"Saghir SA","year":"2024","unstructured":"Saghir SA, Shams N, Veliz L, et al.. Non-alcoholic fatty liver disease: genetic susceptibility. Arch Clin Toxicol. 2024, 6:33-47. 10.46439\/toxicology.6.030","journal-title":"Arch Clin Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref4","article-title":"Improvements in noninvasive markers of MASH and fibrosis were associated with histological MASH resolution with tirzepatide treatment on non-cirrhotic MASH","volume":"80","author":"Loomba R","year":"2024","unstructured":"Loomba R, Boursier J, Bugianesi E, et al.. Improvements in noninvasive markers of MASH and fibrosis were associated with histological MASH resolution with tirzepatide treatment on non-cirrhotic MASH. Cochrane Library. 2024, 80:1262-3.","journal-title":"Cochrane Library"},{"key":"ref5","article-title":"Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: observations from the ENLIVEN Phase2b trial with pegozafermin","volume":"80","author":"Alkhouri N","year":"2024","unstructured":"Alkhouri N. Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: observations from the ENLIVEN Phase2b trial with pegozafermin. Cochrane Library. 2024, 80:444-5.","journal-title":"Cochrane Library"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108777","article-title":"FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)","volume":"38","author":"Albert SG","year":"2024","unstructured":"Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabetes Complications. 2024, 38:108777. 10.1016\/j.jdiacomp.2024.108777","journal-title":"J Diabetes Complications"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba R","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013, 10:686-90. 10.1038\/nrgastro.2013.171","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.08.001","article-title":"Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union","volume":"23","author":"Rehm J","year":"2013","unstructured":"Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013, 23:89-97. 10.1016\/j.euroneuro.2012.08.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301239","article-title":"Genetic determinants of alcoholic liver disease","volume":"61","author":"Stickel F","year":"2012","unstructured":"Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut. 2012, 61:150-9. 10.1136\/gutjnl-2011-301239","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong VW","year":"2012","unstructured":"Wong VW, Chu WC, Wong GL, et al.. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012, 61:409-15. 10.1136\/gutjnl-2011-300342","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31139","article-title":"Bespoken nanoceria: an effective treatment in experimental hepatocellular carcinoma","volume":"72","author":"Fern\u00e1ndez-Varo G","year":"2020","unstructured":"Fern\u00e1ndez-Varo G, Perram\u00f3n M, Carvajal S, et al.. Bespoken nanoceria: an effective treatment in experimental hepatocellular carcinoma. Hepatology. 2020, 72:1267-82. 10.1002\/hep.31139","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh S","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015, 13:643-54.e1-9; quiz e39-40. 10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws453","article-title":"Low-risk lifestyle, coronary calcium, cardiovascular events, and mortality: results from MESA","volume":"178","author":"Ahmed HM","year":"2013","unstructured":"Ahmed HM, Blaha MJ, Nasir K, et al.. Low-risk lifestyle, coronary calcium, cardiovascular events, and mortality: results from MESA. Am J Epidemiol. 2013, 178:12-21. 10.1093\/aje\/kws453","journal-title":"Am J Epidemiol"},{"key":"ref14","unstructured":"Nursing Network. Clinical predictors of progression from non-alcoholic fatty liver disease to cirrhosis. a narrative review. (2025). https:\/\/www.nursingnetwork.com\/newsletters\/385."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.12.022","article-title":"Predicting risk of chronic liver disease in Chinese adults: external validation of the CLivD score","volume":"80","author":"Pang Y","year":"2024","unstructured":"Pang Y, \u00c5berg F, Chen Z, Li L, Kartsonaki C. Predicting risk of chronic liver disease in Chinese adults: external validation of the CLivD score. J Hepatol. 2024, 80:e264-6. 10.1016\/j.jhep.2023.12.022","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen J","year":"2025","unstructured":"Armisen J, Rauschecker M, Sarv J, et al.. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J Hepatol. 2025, 83:31-42. 10.1016\/j.jhep.2024.12.046","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.024","article-title":"Multiple negative fecal immunochemical tests reduce risk of advanced neoplasia in a colonoscopy surveillance program","volume":"21","author":"Wassie MM","year":"2023","unstructured":"Wassie MM, Young GP, Winter JM, et al.. Multiple negative fecal immunochemical tests reduce risk of advanced neoplasia in a colonoscopy surveillance program. Clin Gastroenterol Hepatol. 2023, 21:2389-98.e2. 10.1016\/j.cgh.2022.12.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.35511","article-title":"New-onset age of nonalcoholic fatty liver disease and cancer risk","volume":"6","author":"Liu C","year":"2023","unstructured":"Liu C, Liu T, Zhang Q, et al.. New-onset age of nonalcoholic fatty liver disease and cancer risk. JAMA Netw Open. 2023, 6:e2335511. 10.1001\/jamanetworkopen.2023.35511","journal-title":"JAMA Netw Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10667-5","article-title":"The contribution of genetics and epigenetics to MAFLD susceptibility","volume":"18","author":"Moretti V","year":"2024","unstructured":"Moretti V, Romeo S, Valenti L. The contribution of genetics and epigenetics to MAFLD susceptibility. Hepatol Int. 2024, 18:848-60. 10.1007\/s12072-024-10667-5","journal-title":"Hepatol Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee QM","year":"2023","unstructured":"Anstee QM, Berentzen TL, Nitze LM, et al.. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2023, 36:100780. 10.1016\/j.lanepe.2023.100780","journal-title":"Lancet Reg Health Eur"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001077","article-title":"The Liver Meeting: San Diego, California, Nov 15-19, 2024","volume":"80","year":"2024","unstructured":"The Liver Meeting. San Diego, California, Nov 15-19, 2024. Hepatology. 2024, 80:S1-2011. 10.1097\/HEP.0000000000001077","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor RS","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, et al.. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020, 158:1611-25.e12. 10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.30436","article-title":"Simulation of long-term outcomes in patients with nonalcoholic fatty liver disease","volume":"5","author":"Huang JF","year":"2022","unstructured":"Huang JF, Yu ML, Chuang WL. Simulation of long-term outcomes in patients with nonalcoholic fatty liver disease. JAMA Netw Open. 2022, 5:e2230436. 10.1001\/jamanetworkopen.2022.30436","journal-title":"JAMA Netw Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le P","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al.. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025, 8:e2454707. 10.1001\/jamanetworkopen.2024.54707","journal-title":"JAMA Netw Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease","volume":"4","author":"Younossi ZM","year":"2021","unstructured":"Younossi ZM, Felix S, Jeffers T, et al.. Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw Open. 2021, 4:e2123923. 10.1001\/jamanetworkopen.2021.23923","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi ZM","year":"2021","unstructured":"Younossi ZM, Stepanova M, Ong J, et al.. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021, 19:580-9.e5. 10.1016\/j.cgh.2020.05.064","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson S","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015, 62:1148-55. 10.1016\/j.jhep.2014.11.034","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon TG","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021, 70:1375-82. 10.1136\/gutjnl-2020-322786","journal-title":"Gut"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/408535-clinical-predictors-of-progression-from-metabolic-dysfunction-associated-steatotic-liver-disease-to-cirrhosis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T03:28:07Z","timestamp":1757042887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/408535-clinical-predictors-of-progression-from-metabolic-dysfunction-associated-steatotic-liver-disease-to-cirrhosis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.91628","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}